MiMedx

MiMedx is an American biomedical and regenerative-medicine company headquartered in Marietta, Georgia. Its business is centered on human placental tissues collected after birth, including amniotic membrane, chorion, umbilical cord and related birth-tissue components. These materials are processed into allografts and other medical products intended primarily for wound-management applications, including chronic and hard-to-heal wounds such as diabetic foot ulcers, as well as burns, surgical wounds and other tissue-repair needs. The company was founded in 2008 by Parker H. Petit, a healthcare executive who had previously founded Life Systems and later led Matria Healthcare. MiMedx became a public company on NASDAQ in April 2012 under the ticker MDXG. Its early growth was supported by sales of placental-tissue products to healthcare providers and government-related customers, particularly the U.S. Department of Veterans Affairs. By 2012, reported revenue was approximately $27 million, and the company was later included among Fortune's fastest-growing companies in 2017. MiMedx's growth was accompanied by regulatory, accounting and governance disputes. Beginning in 2013, the U.S. Food and Drug Administration examined whether certain amniotic products qualified for treatment under Section 361 of the Public Health Service Act. That classification determines whether a tissue product can be marketed under a comparatively less burdensome regulatory pathway or instead must satisfy requirements applicable to drugs or biologics. The company also faced disputes concerning the Veterans Affairs purchasing and product-storage rules, as well as allegations that it had improperly recognized revenue by shipping products to customers before demand or acceptance was sufficiently established. From 2017 through 2019, short sellers, investors, regulators and prosecutors focused on alleged channel stuffing, misleading financial reporting, deficient internal controls and management conduct. The Securities and Exchange Commission investigated the company, the U.S. Department of Justice opened a criminal investigation, and MiMedx's senior leadership changed substantially. Petit, Chief Operating Officer William Taylor and Chief Financial Officer Michael Senken left the company in 2018; MiMedx stated that they had been terminated for cause rather than voluntarily resigning. The company was delisted from NASDAQ in November 2018 and traded on OTC Pink while its accounting records were reviewed and restated. Timothy R. Wright became chief executive officer in May 2019 and led a restructuring intended to restore financial reporting, regulatory compliance and investor confidence. The company brought in new senior leaders, worked with auditors and regulators, completed a required restatement, and filed overdue financial reports. In August 2020, it announced $150 million in concurrent private-equity and debt financing. NASDAQ approved MiMedx's application to relist its common stock on October 30, 2020. The legal fallout continued during the turnaround. In November 2019, MiMedx agreed to pay $1.5 million to resolve SEC allegations concerning materially misleading revenue reporting. In April 2020, it agreed to pay $6.5 million to resolve a U.S. Department of Justice case alleging inflated prices charged to the Department of Veterans Affairs. In a separate criminal case, Petit and Taylor were convicted on different securities-fraud-related counts in 2020 and each received a one-year prison sentence; Petit was also fined $1 million and Taylor $250,000. MiMedx has positioned itself as a specialist in placental-tissue regenerative medicine rather than as a broad pharmaceutical company. Its principal commercial identity remains tied to allografts for wound care and tissue repair. In November 2020, the company said it had supplied more than two million allografts. The available reference material does not establish a current chief executive, current product portfolio beyond the broad allograft business, or a current official website URL; those fields are therefore left limited or null where appropriate.

MiMedx was established in 2008 by Parker H. Petit, a healthcare entrepreneur whose earlier businesses included Life Systems and Matria Healthcare. Petit became MiMedx's chief executive in 2009. The company developed a business around the recovery and processing of tissues obtained after childbirth, particularly placental and amniotic tissues. These materials were converted into allografts intended for wound care and other regenerative-medicine applications. MiMedx entered the public markets in April 2012, when its shares began trading on NASDAQ under the symbol MDXG. The company reported approximately $27 million in revenue for 2012. Its customer base included healthcare providers and government purchasers, with the Department of Veterans Affairs becoming an important commercial relationship. The company grew rapidly and was recognized by Fortune in 2017 as one of its fastest-growing companies. Regulatory questions emerged early in the company's development. In 2013, the FDA reviewed whether MiMedx's amniotic products qualified under Section 361 of the Public Health Service Act. Products meeting that framework can generally be marketed under a tissue-based regulatory pathway, while products outside it may need to satisfy more stringent requirements applicable to drugs or biologics. That same period also brought a dispute involving the VA's classification and purchasing of MiMedx allografts. MiMedx believed that a competitor, Organogenesis, had influenced certain regulatory and procurement decisions, although the company did not establish that allegation. MiMedx sued Organogenesis in December 2014 over alleged interference with its VA business, then withdrew the action the following month. A later VA storage-policy change in 2016 threatened to require MiMedx to accept the return of certain products and potentially reduce revenue that had already been recorded. The policy was subsequently interpreted in a way that reduced the expected impact. Government relations became a recurring part of reporting about the company. Georgia Senator Johnny Isakson made calls to federal agencies on behalf of Petit and MiMedx, but the available account states that there was no evidence he caused the agencies to provide relief. From 2017, short sellers and activist investors increasingly challenged MiMedx's accounting. Critics alleged that the company had used channel stuffing or other practices to record revenue prematurely. MiMedx rejected these accusations and publicly criticized its detractors. It announced in March 2017 that an internal review had not found wrongdoing, replaced its external auditor Cherry Bekaert with Ernst & Young in August, and then became the subject of SEC and Justice Department scrutiny. The company also faced questions about whether it had properly reported payments to physicians under the Physician Payments Sunshine Act. The Wall Street Journal reported that MiMedx treated the law as inapplicable to its products, while some competitors reported comparable payments. The management crisis intensified in 2018. Petit, William Taylor and Michael Senken left the company, and MiMedx said that they had been terminated for cause. The SEC pursued claims against Petit and Senken, while federal prosecutors investigated the company's accounting and dealings with the VA. Three VA employees were indicted in May 2018 for accepting bribes from the company, according to the supplied reference material. MiMedx delayed an earnings announcement and later acknowledged that its financial statements would need significant review and restatement. The company was delisted from NASDAQ in November 2018 and moved to OTC Pink trading. During the subsequent restructuring, MiMedx said that former senior executives had authorized a covert video-surveillance effort known internally as Project Snow White, allegedly intended to expose or undermine whistleblowers. The company also asserted that prior managers had withheld or misrepresented information to auditors and had disregarded revenue-recognition requirements. Ernst & Young resigned from the audit in December 2018. David Coles served as CEO during part of this transition, and Timothy R. Wright became CEO in May 2019. Wright's turnaround program emphasized improved governance, compliance and disclosure. By August 2019, most of the previous executive team had departed. MiMedx worked with auditors and regulators, completed a restatement reaching back to 2012, filed its 2019 annual report and its first-quarter 2020 report, and raised $150 million through concurrent private-equity and debt financings by August 2020. The company subsequently received approval to relist on NASDAQ on October 30, 2020. Legal proceedings continued alongside the operational recovery. In November 2019, MiMedx agreed to pay $1.5 million to settle SEC allegations concerning wide-ranging fraud and the inflation of revenue in periodic filings. In April 2020, it agreed to pay $6.5 million to resolve a Justice Department case alleging inflated prices charged to the VA. The company also received a $10 million Paycheck Protection Program loan in April 2020, attracting criticism because the program was intended to support smaller businesses affected by the COVID-19 pandemic. The criminal case against former executives reached a verdict in November 2020. Petit was found guilty of securities fraud but not guilty of conspiracy to commit securities fraud. Taylor was found guilty of conspiracy but not guilty of the substantive securities-fraud count. Both were sentenced to one year in prison; Petit received a $1 million fine and Taylor a $250,000 fine. By November 2020, MiMedx said it had supplied more than two million allografts. The available sources describe the company's continuing identity as a placental-tissue regenerative-medicine business, but do not provide enough current information to document its present executive team, precise current product names or current corporate website.

• 2020

  Financing, restatement and relisting process

  [1]MiMedxen.wikipedia.org

  MiMedx raised $150 million in private-equity and debt financing, completed required reporting work and received NASDAQ relisting approval.

• 2019

  Wright begins turnaround

  [1]MiMedxen.wikipedia.org

  Timothy R. Wright became CEO and initiated a governance, reporting and organizational restructuring.

• 2018

  Leadership exits and NASDAQ delisting

  [1]MiMedxen.wikipedia.org

  Several senior executives left amid investigations, and MiMedx was delisted from NASDAQ in November.

• 2017

  Accounting allegations become public

  [1]MiMedxen.wikipedia.org

  Short sellers and investors began publicizing allegations concerning revenue recognition and channel stuffing.

• 2013

  FDA reviews Section 361 eligibility

  [1]MiMedxen.wikipedia.org

  The FDA examined the regulatory classification of MiMedx's amniotic products.

• 2012

  NASDAQ listing

  [1]MiMedxen.wikipedia.org

  MiMedx began trading on NASDAQ under the ticker MDXG.

• 2009

  Petit becomes chief executive

  [1]MiMedxen.wikipedia.org

  Parker H. Petit became MiMedx's CEO.

• 2008

  MiMedx is founded

  [1]MiMedxen.wikipedia.org

  Parker H. Petit founded MiMedx as a biomedical company focused on products derived from placental and other birth tissues.

A specialized regenerative-medicine company focused on processing human birth tissues into allografts for wound care and tissue repair.

• Regenerative medicine and wound care

  Placental-tissue allografts

  MiMedx's central product category consists of allografts made from tissues recovered after birth, especially placental tissues. The products are intended for medical use in wound management and tissue repair. Applications described in the reference material include persistent wounds such as diabetic foot ulcers, burns and other urgent or difficult-to-heal wounds.

• Biologic and tissue-based medical products

  Amniotic and chorionic membrane products

  These products use processed layers of the placenta, including amniotic and chorionic membrane. Their commercial and regulatory treatment was central to the FDA's review of whether MiMedx products qualified under the Section 361 tissue pathway. The materials were marketed for clinical wound-care and regenerative applications rather than as conventional pharmaceutical drugs.

• Regenerative medicine

  Umbilical-cord-derived tissue products

  MiMedx has described birth tissues including umbilical cord among the source materials used in its regenerative-medicine portfolio. The available material does not identify a complete current product list or individual commercial brand names, so this entry is limited to the documented product category.

• 2020

  Department of Justice VA pricing settlement

  MiMedx agreed to pay $6.5 million to resolve allegations that it charged inflated prices to the Department of Veterans Affairs.

  Source

• 2020

  Former executives convicted in securities case

  Parker H. Petit and William Taylor were convicted on different securities-fraud-related counts following a federal trial and were each sentenced to one year in prison.

  Source

• 2020

  Scrutiny over Paycheck Protection Program loan

  MiMedx's receipt of a $10 million federally backed PPP loan drew public criticism because the company had substantial employees and had recently faced serious legal and financial problems.

  Source

• 2019

  SEC settlement over financial reporting

  MiMedx agreed to pay $1.5 million to resolve SEC allegations involving materially inflated revenue and misleading periodic filings.

  Source

• 2018

  Management and whistleblower controversy

  MiMedx later alleged that former executives had authorized a covert surveillance project known as Project Snow White to target or undermine whistleblowers and had withheld information from auditors and regulators.

  Source

• 2018

  Physician-payment reporting dispute

  The company faced questions over whether payments to physicians should have been reported under the Physician Payments Sunshine Act. Reporting described a disagreement between MiMedx's interpretation and the treatment of comparable payments by competitors.

  Source

• 2017

  Revenue-recognition and channel-stuffing allegations

  Short sellers and other investors alleged that MiMedx recognized revenue improperly, including through channel stuffing. The allegations contributed to SEC and Justice Department investigations and a major corporate restructuring.

  Source

Read more

• 2020

  Accept Paycheck Protection Program financingOther

  Background

  The COVID-19 pandemic disrupted business activity, while earlier legal and financial problems had constrained MiMedx's access to other funding channels.

  Action taken

  MiMedx obtained a $10 million federally backed PPP loan.

  Aftermath

  The loan attracted criticism because the company was larger and more established than many businesses commonly associated with the program.

  Paycheck Protection Program loan. $10 million (April 2020)

  Source

• 2020

  Relist common stock on NASDAQOther

  Background

  MiMedx had been removed from NASDAQ in 2018 because of unresolved reporting and compliance issues.

  Action taken

  After completing the required restatement and filing overdue reports, MiMedx received NASDAQ approval to relist its common stock.

  Aftermath

  The approval marked a significant step in the company's financial and governance turnaround.

  Source

• 2019

  Launch governance and financial turnaroundStrategy

  Background

  MiMedx needed to restore credible financial reporting, resolve regulatory issues and rebuild investor confidence.

  Action taken

  Under CEO Timothy R. Wright, the company replaced much of its senior leadership, worked with auditors and regulators, restated historical results and emphasized transparency and timely disclosure.

  Aftermath

  MiMedx completed required filings, raised $150 million in financing by August 2020 and obtained approval to relist on NASDAQ.

  Concurrent private-equity and debt financing. $150 million raised (By August 2020)

  Source

• 2018

  Remove senior managementOther

  Background

  Investigations into alleged accounting improprieties and management conduct intensified.

  Action taken

  MiMedx said that Parker H. Petit, William Taylor and Michael Senken had been terminated for cause.

  Aftermath

  The company entered a prolonged restructuring period, was delisted from NASDAQ and traded on OTC Pink while its accounts were reviewed.

  Source

• 2017

  Replace external auditor and investigate allegationsStrategy

  Background

  Public allegations concerning revenue recognition and channel stuffing increased pressure on MiMedx's internal controls and financial reporting.

  Action taken

  MiMedx announced that an internal review had not uncovered wrongdoing, dismissed Cherry Bekaert as its external auditor and hired Ernst & Young.

  Aftermath

  The company later faced delayed filings, a substantial restatement and expanded regulatory and criminal investigations.

  Source

1. 1MiMedxen.wikipedia.org